Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cancer patients who responded to drug get continued access in rollover trial

NCT ID NCT06506955

First seen Mar 11, 2026 · Last updated May 24, 2026 · Updated 11 times

Summary

This study offers ongoing futibatinib treatment to about 15 people with advanced or metastatic cancer who were already benefiting from the drug in a previous study. The main goal is to track long-term safety, including side effects. Participants continue their current dose as long as they are doing well and the risks are acceptable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centro Integral Oncologico

    Madrid, 28050, Spain

  • Hospital Universitari, Vall d'Hebron

    Barcelona, 8035, Spain

  • Institut De Cancerologie Strasbourg

    Strasbourg, 67033, France

  • Institut Paoli-Calmettes

    Marseille, 13009, France

  • Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • Sarah Cannon Research Institute UK

    London, W1G 6AD, United Kingdom

  • Severance Hospital

    Seoul, 3722, South Korea

  • University College London Hospitals NHS Foundation Trust

    London, W1T 7HA, United Kingdom

  • University of California, San Francisco (UCSF)

    San Francisco, California, 94143, United States

Conditions

Explore the condition pages connected to this study.